Pricing & Access· August 18, 2026 · 16 min read
DTX401's August 23 PDUFA: Payers Face a Cornstarch-Replacement Gene Therapy
By Ran Chen#Gene Therapy#Rare Disease#Medicaid
Section
Pricing & Access
Coverage, formulary strategy, prior authorization, patient assistance, IRA negotiation, and gross-to-net pressure.
173 articles · Last updated
Pricing & Access· August 18, 2026 · 18 min read
Ziihera's August 25 Gastric Decision: Bispecific vs Trastuzumab Biosimilars
By Ran Chen#Oncology#HER2#Biosimilars
Pricing & Access· August 17, 2026 · 25 min read
Medicaid's September 10 Deadline: The Coverage Trade for GENEROUS Pricing
By Ran Chen#Medicaid#Drug Pricing#Payer Policy
Pricing & Access· August 17, 2026 · 25 min read
Tavneos on Formularies as FDA Moves to Withdraw: The Coverage Dilemma
Pricing & Access· August 16, 2026 · 18 min read
Hepatitis C Treatment Access in 2026: Generic Economics, PA, and Sobriety
Pricing & Access· August 13, 2026 · 20 min read
Epilepsy Treatment Access (2026): From $0.02 Generics to Zorevunersen
By Ran Chen#Antiepileptic Drugs#Antisense#Rare Disease
Pricing & Access· August 13, 2026 · 22 min read
IBD Treatment Access (2026): Stelara & Humira Biosimilars Meet IL-23
Pricing & Access· August 8, 2026 · 14 min read
Novo Nordisk portfolio dossier (Q2 2026): Wegovy, CagriSema & obesity pipeline
By Ran Chen#Novo Nordisk#Semaglutide#Wegovy
Pricing & Access· August 3, 2026 · 15 min read
EU Pharmaceutical Procurement by the Numbers (2026): What 35,000 TED Tenders Reveal
By Ran Chen#Market Access#Generic Drugs#Drug Pricing
Pricing & Access· August 1, 2026 · 23 min read